Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study

MT Newswires Live

Jul 27

Neumora Therapeutics (NMRA) said Monday a repeat safety study of its experimental oral obesity drug, NMRA-215, found no unexpected in-life adverse findings, supporting plans to file an investigational new drug application in the fourth quarter of 2026.

The company said it repeated the 13-week rat study after an earlier study reported unexpected findings in five of 142 animals.

Neumora said an audit found discrepancies that resulted in critical audit observations in how the earlier study was conducted, and the new results, along with previous studies in rats and dogs, suggest the earlier findings were not caused by NMRA-215.

Neumora said its preclinical studies showed NMRA-215 produced weight loss as a monotherapy, increased weight loss when used with semaglutide, and improved markers linked to heart and metabolic health.

It added that it expects to begin a Phase 1 clinical trial by the end of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2654010397"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654010397\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654010397?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654010397","market":"sg","top_or_hot":-1,"title":"Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study","media":"MT Newswires Live","content":"<html><body><p> Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (NMRA) said Monday a repeat safety study of its experimental oral obesity drug, NMRA-215, found no unexpected in-life adverse findings, supporting plans to file an investigational new drug application in the fourth quarter of 2026.</p><p>The company said it repeated the 13-week rat study after an earlier study reported unexpected findings in five of 142 animals.</p><p>Neumora said an audit found discrepancies that resulted in critical audit observations in how the earlier study was conducted, and the new results, along with previous studies in rats and dogs, suggest the earlier findings were not caused by NMRA-215.</p><p>Neumora said its preclinical studies showed NMRA-215 produced weight loss as a monotherapy, increased weight loss when used with semaglutide, and improved markers linked to heart and metabolic health.</p><p>It added that it expects to begin a Phase 1 clinical trial by the end of 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-27 20:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (NMRA) said Monday a repeat safety study of its experimental oral obesity drug, NMRA-215, found no unexpected in-life adverse findings, supporting plans to file an investigational new drug application in the fourth quarter of 2026.</p><p>The company said it repeated the 13-week rat study after an earlier study reported unexpected findings in five of 142 animals.</p><p>Neumora said an audit found discrepancies that resulted in critical audit observations in how the earlier study was conducted, and the new results, along with previous studies in rats and dogs, suggest the earlier findings were not caused by NMRA-215.</p><p>Neumora said its preclinical studies showed NMRA-215 produced weight loss as a monotherapy, increased weight loss when used with semaglutide, and improved markers linked to heart and metabolic health.</p><p>It added that it expects to begin a Phase 1 clinical trial by the end of 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2654010397","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654010397","pubTimestamp":1785154877,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neumora Therapeutics  said Monday a repeat safety study of its experimental oral obesity drug, NMRA-215, found no unexpected in-life adverse findings, supporting plans to file an investigational new drug application in the fourth quarter of 2026.The company said it repeated the 13-week rat study after an earlier study reported unexpected findings in five of 142 animals.Neumora said an audit found discrepancies that resulted in critical audit observations in how the earlier study was conducted, and the new results, along with previous studies in rats and dogs, suggest the earlier findings were not caused by NMRA-215.Neumora said its preclinical studies showed NMRA-215 produced weight loss as a monotherapy, increased weight loss when used with semaglutide, and improved markers linked to heart and metabolic health.It added that it expects to begin a Phase 1 clinical trial by the end of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NMRA":"Neumora Therapeutics, Inc.","IND":"Xtrackers Nifty 500 India ETF"},"translate_title":"Neumora Therapeutics 计划在重复毒理学研究后第四季度向肥胖药物提交 IND 申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IND":1.5,"NMRA":1.5},"content_text":"Neumora Therapeutics (NMRA) said Monday a repeat safety study of its experimental oral obesity drug, NMRA-215, found no unexpected in-life adverse findings, supporting plans to file an investigational new drug application in the fourth quarter of 2026.The company said it repeated the 13-week rat study after an earlier study reported unexpected findings in five of 142 animals.Neumora said an audit found discrepancies that resulted in critical audit observations in how the earlier study was conducted, and the new results, along with previous studies in rats and dogs, suggest the earlier findings were not caused by NMRA-215.Neumora said its preclinical studies showed NMRA-215 produced weight loss as a monotherapy, increased weight loss when used with semaglutide, and improved markers linked to heart and metabolic health.It added that it expects to begin a Phase 1 clinical trial by the end of 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}